Relapse after omalizumab discontinuation in chronic spontaneous urticaria
Year: 2026
Type: dataset
Abstract: Post-cessation relapse is difficult to compare because patient selection, outcome definitions and observation periods vary. To synthesize relapse after omalizumab cessation in CSU and CSU-predominant cohorts and examine interpretive limitations. We updated searches in PubMed, Embase, Scopus and Web of Science on 23 October 2026. Source-defined clinical relapse after complete cessation was separated from taper failure and retreatment. Random-effects logit pooling and sensitivity analyses addressed population, response, follow-up, overlapping reports and statistical models. Forty-one stopping risk sets (2,643 patients; 1,209 source-reported events) yielded a pooled proportion of 46.6% (95% CI 40.1–53.2%; I2 = 87.7%; prediction interval 16.0–79.9%). CSU-only pooling gave 47.1% (95% CI 40.2–54.2%). Results reflect different follow-up periods, not a common time-specific risk. Eighty-three candidate full reports were unavailable. Three newly verified small risk sets contributed 0/1, 0/2 and 3/5 outcomes; excluding sets with fewer than ten stoppers yielded 46.3%. Pure dose reduction was supported by one observational arm. Confirmed type IIb-specific relapse counts were unavailable. Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.
Source: Figshare
Authors: Muhammed Burak Yücel, Esranur Ünal
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225916092
Cites:
Cited by:
Related to: